Profile data is unavailable for this security.
About the company
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
- Revenue in JPY (TTM)81.47bn
- Net income in JPY8.40bn
- Incorporated1955
- Employees1.78k
- LocationZeria Pharmaceutical Co Ltd10-11, Nihombashi Kobuna-choCHUO-KU 103-8351JapanJPN
- Phone+81 336632351
- Fax+81 336632352
- Websitehttps://www.zeria.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASKA Pharmaceutical Holdings Co Ltd | 63.57bn | 5.98bn | 62.23bn | 762.00 | 9.65 | 0.8996 | 7.47 | 0.9789 | 210.94 | 210.94 | 2,243.73 | 2,263.17 | 0.7056 | 1.64 | 3.86 | 83,419,940.00 | 6.63 | 4.63 | 8.44 | 5.87 | 49.38 | 46.94 | 9.40 | 6.76 | 1.71 | -- | 0.1064 | 14.86 | 3.94 | 6.12 | 78.03 | 34.04 | -37.89 | 23.36 |
| Katakura Industries Co., Ltd. | 38.12bn | 2.89bn | 71.10bn | 1.04k | 22.96 | 0.8565 | 12.33 | 1.87 | 87.92 | 87.92 | 1,158.05 | 2,357.16 | 0.2725 | 1.99 | 5.37 | 36,650,960.00 | 2.17 | 2.35 | 2.79 | 3.34 | 38.62 | 37.75 | 7.97 | 8.32 | 2.56 | -- | 0.1026 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| JCR Pharmaceuticals Co Ltd | 35.26bn | -437.00m | 90.26bn | 934.00 | -- | 1.54 | 28.87 | 2.56 | -3.49 | -3.49 | 281.91 | 451.84 | 0.338 | 0.4791 | 2.15 | 37,747,320.00 | -0.3864 | 8.66 | -0.5681 | 13.46 | 71.44 | 74.51 | -1.14 | 18.24 | 0.9827 | -0.3874 | 0.3325 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Kyorin Pharmaceutical Co Ltd | 119.73bn | 4.82bn | 96.33bn | 2.04k | 17.79 | 0.6588 | 10.42 | 0.8045 | 83.83 | 83.83 | 2,084.19 | 2,263.35 | 0.6745 | 1.21 | 3.18 | 58,635,650.00 | 2.71 | 3.05 | 3.36 | 3.79 | 42.87 | 47.11 | 4.02 | 4.76 | 1.74 | -- | 0.1593 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
| Nxera Pharma Co Ltd | 29.28bn | -3.71bn | 102.22bn | 350.00 | -- | 1.51 | 405.63 | 3.49 | -41.70 | -41.70 | 332.11 | 753.72 | 0.194 | 2.57 | 6.61 | 83,642,860.00 | -2.46 | -0.6588 | -2.76 | -0.7036 | 75.27 | 89.83 | -12.68 | -4.46 | 3.90 | -6.02 | 0.5060 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
| Zeria Pharmaceutical Co Ltd | 81.47bn | 8.40bn | 117.98bn | 1.78k | 11.66 | 1.11 | 7.23 | 1.45 | 190.47 | 190.47 | 1,848.22 | 2,002.47 | 0.5316 | 1.50 | 3.60 | 45,846,530.00 | 5.49 | 3.89 | 8.46 | 6.28 | 72.99 | 71.93 | 10.33 | 7.57 | 0.9178 | -- | 0.3244 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Mochida Pharmaceutical Co Ltd | 104.51bn | 4.53bn | 124.40bn | 1.52k | 25.99 | 0.9116 | 16.74 | 1.19 | 127.75 | 127.75 | 2,945.16 | 3,641.81 | 0.6639 | 1.80 | 3.42 | 68,662,940.00 | 2.88 | 4.37 | 3.41 | 5.31 | 49.61 | 52.47 | 4.34 | 6.71 | 3.50 | -- | 0.00 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Torii Pharmaceutical Co Ltd | 58.84bn | 5.28bn | 134.35bn | 583.00 | 24.85 | 1.09 | 23.58 | 2.28 | 187.71 | 187.71 | 2,093.33 | 4,271.84 | 0.4411 | 2.74 | 2.30 | 100,924,500.00 | 3.96 | 6.52 | 4.39 | 7.35 | 44.46 | 49.55 | 8.97 | 17.98 | 5.19 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| Towa Pharmaceutical Co Ltd | 243.94bn | 15.78bn | 145.33bn | 4.59k | 8.80 | 0.8728 | 4.20 | 0.5957 | 320.50 | 320.50 | 4,956.02 | 3,232.16 | 0.5838 | 1.52 | 3.93 | 53,169,570.00 | 3.78 | 4.21 | 4.56 | 5.63 | 36.10 | 39.23 | 6.47 | 7.23 | 1.63 | -- | 0.581 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
Data as of Nov 22 2024. Currency figures normalised to Zeria Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
8.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.22m | 2.30% |
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 975.30k | 1.84% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 463.20k | 0.87% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 437.20k | 0.82% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 321.20k | 0.61% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 277.51k | 0.52% |
| BlackRock Japan Co. Ltd.as of 07 Nov 2024 | 207.20k | 0.39% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 2024 | 192.30k | 0.36% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 150.50k | 0.28% |
| Mellon Investments Corp.as of 07 Nov 2024 | 120.80k | 0.23% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
